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Cardiovascular disease is the leading cause of mortality in all developed nations.  Several 
independent studies have shown that cardiotrophin-1 (CT-1) serum levels are modulated in 
patients with various types of cardiovascular disease including ischemic heart disease, valvular 
heart disease, and accelerated arthrosclerosis. CT-1 is a member of the Interleukin-6 family, or 
gp130 family of cytokines. It is also known to induce cardiomyocyte hypertrophy in vitro and in 
vivo, and is a critical component for cardiomyocyte survival. CT-1 is a naturally occurring 
protein with a molecular mass of approximately 21.5 kD and a 200 amino acid long sequence, it 
was discovered in a cDNA screen of murine stem cells and was originally identified in 
cardiomyocytes. Since then, CT-1 expression has been reported in several other tissues including 
skeletal muscle, liver, ovary, kidney and lung.   
Interestingly, our studies reveal that CT-1 protein expression is significantly modulated in 
adipose tissue following high fat feeding in C57BL/6 mice. Of note, we did not observe 
regulation of CT-1 expression in white adipose tissue in human obesity and Type II Diabetes 
Mellitus (T2DM). We can readily detect CT-1 in the media of cultured adipocytes. This study 
suggests that CT-1 secretion from murine adipose tissue may be an important contributor to the 
levels of circulating CT-1. In summary, our studies demonstrate that CT-1 is an adipokine that is 





1.1 Adipose Tissue 
Studies over the last two decades have established adipose tissue as a dynamic organ that 
carries out several important physiological processes. There are two distinct classifications of 
adipose tissue: white adipose tissue (WAT) and brown adipose tissue (BAT).  White adipose 
tissue accounts for the majority of fat present in adult humans and is a critical site for energy 
homeostasis, insulin signaling and endocrine action. Brown adipose tissue is predominantly 
responsible for non-shivering thermogenesis via the mitochondrial protein uncoupling protein-1 
(UCP-1)  proton transport during lipid oxidation (1). Brown fat has been well established as an 
important fat depot in postnatal babies and in a variety of mammals. To much surprise to the 
scientific community, several recent studies using 
18
F-fluorodeoxyglucose-positron emission 
tomography and computed tomography suggest that BAT depots are also present in the thoracic 
and supraclavicular regions of adult humans (2;3). Additional studies suggest that this adipose 
tissue may be metabolically active BAT due to the presence UCP-1, an important component in 
BAT classification (4). Studies conducted by the Cinti group in 2010 revealed surprising 
evidence suggesting that brown adipocytes are detectable in subcutaneous WAT in mice (5). 
These observations have increased interest in the potential use of brown adipocytes in correcting 
WAT pathologies.   
 Adipose tissue is comprised of a variety of cell types including endothelial cells, blood 
cells, fibroblasts, pericytes, preadipocytes, macrophages and other immune cells (6). However, 
the predominant cells present in adipose tissue are mature adipocytes. Brown and white 
adipocytes require key transcription factors that are necessary to promote preadipocyte 
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differentiation into mature adipocytes. As shown in Figure 1, these transcriptional regulators 
include critical factors such as peroxisome proliferator-activated receptorγ (PPARγ) and other 
transcription factor families including CCAAT/enhancer binding proteins, STATs, and KLF 
proteins.  
1.2 White Adipocytes 
White adipocytes are generally spherical cells with an average diameter in a young 
animal of less than 10µm, however this size can increase to as much as 100μm particularly in the 
epididymal fat depots (7). The organelles of white adipocytes are typically subjected to a 
confined arrangement due to the presence of a unilocular lipid droplet that occupies the majority 
of the cytosol. As a result of the imposing mass of this fat deposit, the nucleus is usually 
compressed between the fat and plasma membrane. There is a sparse distribution of 
mitochondria in white adipocytes and other classical cellular organelles such as the Golgi and 
smooth and rough endoplasmic reticulum are present. 
White adipose tissue is a key organ that carries out insulin stimulated glucose uptake, an 
important physiological process that is mediated by a signal pathway where insulin activates a 
cascade that results in glucose transporter-4 (GLUT- 4) translocation to the plasma membrane to 
facilitate an increase in the influx of glucose. The details of this mechanism are well studied 
worldwide by numerous groups.  Brown adipocytes do not take up significant amounts of 
glucose upon insulin stimulation, however they are responsive to the sympathetic nervous system 
and norepinephrine can stimulate the uptake of glucose independent of insulin (8). 
1.3 Molecular Regulation of Adipogenesis   
The development of fully differentiated mature adipocytes from precursor cells is an 
elegant progression of the sequential activation of a battery of transcription factors. In white 
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adipocytes, this sequence commences with the activation of members of the AP-1 family of 
transcription factors, and continues with the induction and expression of PPARγ a critical pro-
adipogenic transcription factor (see Figure 1). Other transcription factors facilitate adipocyte 
maturation including STATs, members of the KLF family of proteins, SREBP-1, and members 
C/EBP family. There are also potent negative repressors of adipocyte differentiation including 
Pref-1 and members of the GATA and Wnt families. In addition to these factors, the adipogenic 
program can subjected to humoral regulation. Peptide and steroid hormones can exert paracrine 
and endocrine actions that modulate adipocyte differentiation. 
1.3.1 Positive Effectors of Adipocyte Development  
Activating Protein-1 (AP-1): Activating protein-1 (AP-1) is a large group of 
transcription factors that include v-Jun, c-Jun, JunB, JunD, v-Fos, c-Fos, FosB, Fra1, Fra2 and 
activating transcription factors (ATF2, ATF3/LRF1, B-ATF). These proteins are bZIP (basic 
region leucine zipper) transcription factors. Upon activation, the AP-1 proteins form homodimers 
or hetrodimers before interacting with DNA to regulate genes involved in the differentiation and 
proliferation of various cell types.  In addition, studies have suggested that AP-1 can also be a 
part of cellular pro-apoptotic machinery (9;10). In regards to adipocyte development, in vitro 
studies primarily performed with 3T3-L1 and 3T3-F442A preadipocytes have established a 
strong association with AP-1 transcription factors and adipogenesis. In fact, the mRNA 
expression of c-Fos, c-Jun, Fos-B, and Fra-1 are all induced at the onset of adipocyte 
differentiation (11;12). In 1987 the Spiegelman group demonstrated that AP-1 modulated the 
expression of aP2 particularly via interaction between c-Fos and the FSE2 regulatory sequence 
of the aP2 promoter (13). Additionally, in vivo work was conducted with mice that were 
engineered to have a fat specific expression of A-ZIP/F using the aP2 promoter. In these studies, 
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investigators engineered A-ZIP/F, a dominant negative protein that hinders bZIP-DNA 
interaction and disrupts C/EBP and Jun transcription activity. These mice had impaired WAT 
development and significantly less BAT (14). 
Krüppel-like Factors (KLFs): The nomenclature for this family of transcription factors 
was derived from the strong homology, particularly at the zinc finger DNA interaction domains, 
with the Drosophila embryonic pattern regulator protein Krüppel (15). To date, there are 
seventeen members of the C2H2 zinc finger Krüppel-like family of transcription factors and they 
are implicated in development, cellular differentiation, and proliferation (reviewed in (16)). It is 
interesting to note that members of this family can assume opposing transcriptional roles: some 
being activators of gene transcription, while others act as repressors of transcription. This section 
will focus on KLFs 4, 5 6, and 15 that have been shown to be positive effectors of adipogenesis.  
KLF5 expression is induced during the early stages of adipocyte differentiation and has 
been shown to be necessary for adipocyte differentiation in vitro and in vivo (17). KLF5-siRNA 
expression in 3T3-L1 preadipocytes results in impaired adipocyte differentiation and a 
substantial decrease in lipid accumulation. In addition, KLF5 
+/-  
heterozygote mice have a 
reduction in fat pad size (17). Around the same time in 2005, it was revealed that KLF15 is also 
essential for adipogenesis (18). KLF15 is highly induced during the differentiation of 3T3-L1 
cells and dominant negative mutations and RNAi knockdowns results in attenuated adipocyte 
differentiation (18) . These studies also showed that ectopic expression of KLF15 can confer 
adipogenesis by inducing PPARγ activation in NIH-3T3 cells. KLF15 plays another key role in 
adipocyte physiology as studies have demonstrated an interaction of KLF15 with the GLUT-4 
promoter, indicating a link between adipocyte insulin sensitivity and KLF15 (19). KLF4 is also 
highly expressed in white adipose tissue but it is expressed at much lower levels in vitro in 
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mature 3T3-L1 adipocytes. Further analysis revealed that the enrichment of KLF4 in adipose 
tissue can be attributed to its high expression in preadipocytes of the stromal-vascular fraction of 
white adipose tissue (20). These findings lead to the hypothesis that KLF4 may also be a key 
regulator of adipogenesis. In 2008, studies demonstrated that KLF4 mRNA was induced early in 
3T3-L1 differentiation and siRNA knockdown resulted in marked decreases in lipid 
accumulation (21). KLF6 has also been identified as a positive effector of adipogenesis. KLF6 is 
induced during 3T3-L1 adipogenesis (22), and studies suggest that KLF6 promotes adipocyte 
differentiation by repressing of DLK-1 gene expression in 3T3-L1 preadipocytes (23). Taken 
together, these studies demonstrate that KLF4, KLF5, KLF6 and KLF15 are transcription factors 
that promote adipocyte development.  
CCAAT/Enhancer Binding Proteins (C/EBPs): The C/EBPs is another family of basic 
leucine zipper transcription factors. There are six C/EBP isoforms, all of which possess a highly 
conserved bZIP domain that serves as a point of interaction for homodimerization or 
hetrodimerization with other family members (24). The most common nomenclature for the 
members is: C/EBPα, β, δ, γ, ε, and δ. Both in vivo and in vitro experiments have demonstrated 
that C/EBPα, β, δ promote adipocyte differentiation. McKnight and colleagues presented the first 
set of data to demonstrate the orchestrated induction of these family members during 
adipogenesis. C/EBPβ is primarily induced by methylisobutylxanthine (MIX) and C/EBPδ is 
highly induced by dexamethasone (DEX) in the very early stages of adipogenesis. C/EBPβ and 
C/EBPδ work in concert to trans-activate C/EBPα (25). Loss of function experiments in 3T3-L1 
and NIH-3T3 cell lines confirmed the importance of C/EBPβ and C/EBPδ as inhibition of either 
of these C/EBPs resulted in the attenuation of adipogenesis (26). Interestingly, ectopic 
expression studies with C/EBPα demonstrated that it was sufficient to induce adipogenesis in 
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precursor cell lines that are susceptible to adipogenesis, and in non-precursor fibroblasts (26;27). 
In vivo studies investigating the relevance of the C/EBPs to the adipogenic program have been 
conducted by numerous labs. C/EBPβ and/or δ-deficient mice exhibit defective adipose tissue 
development (28). Studies with C/EBPα-deficient mice revealed a phenotype of substantially 
low lipid accumulation (29;30).  
Sterol Regulatory Element Binding Protein-1 (SREBP-1): This basic helix-loop-helix 
regulatory molecule was originally termed the adipocyte determination and differentiation factor-
1 (ADD-1) by the Spiegelman laboratory in 1993 (31).  ADD-1 was identified in a rat adipocyte 
cDNA expression library screen as a factor that binds to an E-box domain, a DNA recognition 
site for basic helix-loop-helix proteins. Northern blot analysis demonstrated a substantial 
increase in ADD-1 mRNA expression during adipocyte differentiation in three well established 
models of adipocyte development: 3T3-F442A, 3T3-L1, and 10T½ cells.  A mere two months 
later, the Brown and Goldstein laboratory isolated the human homologue of the same protein for 
its ability to bind to the sterol regulatory element in the promoter region of the low-density 
lipoprotein receptor, thus labeling it sterol regulatory element binding protein-1 (SREBP-1) (32). 
To date there are three isoforms of SREBP: SREBP-1a, SREBP-1c and SREBP-2. SREBP-1a 
and SREBP-1c originate from the same gene through utilization of different promoters (33). 
SREBP-1a is the more potent transcription factor due to a longer NH3-terminal DNA binding 
domain (34). SREBP-1c is the predominantly expressed isoform in white adipose tissue (35) and 
a chief regulator of lipogenic gene transcription. SREBP-2 is transcribed from an alternate gene 
and primarily regulates the expression of genes involved in cholesterol biosynthesis (36). 
In vitro evidence suggested that ADD-1/SREBP-1 is a critical factor in adipocyte development. 
Ectopic expression of ADD-1/SREBP-1 in NIH-3T3 fibroblasts in the presence of hormonal 
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induction cocktail resulted in differentiation that was accompanied by increased expression of 
adipocyte specific genes and lipid accumulation (37). In this study, investigators also performed 
experiments to ectopically express a dominant-negative ADD-1 that contained a point mutation 
within the DNA binding domain. This mutation resulted in a profound inhibition of 
differentiation and repression of adipocyte marker genes.  
On the contrary, in vivo studies exploring the involvement of SREBP-1 in adipogenesis 
are less persuasive. Transgenic mice engineered with adipose tissue specific knockout of 
SREBP-1 had minimal inhibition of adipose tissue development with no overt effects on the 
expression of adipocyte marker genes (38). Ectopic expression of a constitutively active SREBP-
1c surprisingly conferred lipodystrophy in mice (39). Other in vivo studies by Yahagi and 
colleagues engineered a double mutant by crossing leptin-deficient ob/ob mice and SREBP-1
-/-
 
mice. These studies also suggested that SREBP-1 was not needed for adipose tissue expansion 
(40). Overall, the data suggest that while there is in vitro evidence to show SREBP-1 is required 
for adipocyte differentiation, the in vivo studies consistently demonstrate that SREBP-1 
expression is not critical for adipose tissue development and/or expansion. 
Signal Transducers and Activators of Transcriptions (STATs): There are seven signal 
transducers and activators of transcription (STAT) proteins designated  STATs  1, 2, 3, 4, 5A, 
5B, and 6 that exhibit unique tissue distributions and regulate the expression of tissue specific 
genes (41).  STAT expression and modulation of gene expression can be cell specific and 
transgenic knockout studies have shown critical roles for every member of the STAT family 
(41).  The STATs are primarily activated by cytokines and hormones. Ligand binding initiates a 
cascade that results in STAT tyrosine phosphorylation, dimerization and translocation to the 
nucleus where STATs modulate transcription (41;42). Several groups have studied STAT 
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biology in fat cells and it is known that STATs 1, 3, 5A, 5B and 6 are expressed in adipocytes. 
The first study of STAT expression in adipocytes demonstrated that STATs 1, 5A and 5B are 
substantially induced during 3T3-L1 adipocyte differentiation (43). Subsequently, Harp and 
colleagues observed similar induction patterns of STATs 5A and 5B in human subcutaneous 
preadipocytes (44). The studies in mouse and human cells revealed similar induction of STATs 
3, 5A, and 5B, but there was a difference in STAT1 induction in mouse and human cells.  
However, it is unlikely that STAT1 plays a critical role in adipocyte development because 
STAT1 knockout mice do not have any apparent body weight abnormalities (45).  
Although the relevance for STAT1 expression during the adipogenic program remains 
unclear, there are several studies that demonstrate a role of STATs 3, 5A and 5B in human and 
murine adipogenesis in a variety of well characterized models. STAT3 expression has been 
shown to increase during the proliferative phase of 3T3-L1 adipogenesis (46), and its expression 
is tightly regulated  by protein inhibitor of activated STAT3 (PIAS3) (47). Investigators   
observed a disruption in adipogenesis using AG490, a JAK2 inhibitor and STAT3 siRNAs (48). 
Additionally, ectopic expression of a dominant negative STAT3 suppresses adipocyte 
differentiation (49). Mice lacking STAT3 in adipose tissue were generated using the aP2 
promoter and exhibited higher body weights and increased adipocyte size compared to wildtype 
littermates (50).  Taken together, these studies suggest a possible role for STAT3 in adipogenesis 
and body weight homeostasis. However, additional studies are necessary to further clarify the 
contribution of STAT3 in adipocyte development and physiology. 
The involvement of STAT5 in adipogenesis has been widely studied. Ectopic expression 
of C/EBPβ and δ in non-precursor cells has been shown to induce adipogenesis (51) in a manner 
that promotes an increase in STAT5A and STAT5B expression (52). PPARγ has also been 
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shown to upregulate the expression of both STAT5 proteins during adipogenesis (53). In 3T3-
F442A preadipocytes, the modulating effect of growth hormone on adipogenesis is attenuated by 
STAT5 antisense oligonucleotides (54) and constitutively active STAT5 can drive adipogenesis 
in this model system (55). Ectopic expression studies and transgenic knockout experiments have 
confirmed the physiological relevance of STAT5 proteins in adipogenesis. Ectopic expression of 
STAT5A induces adipogenesis in 3T3-L1 preadipocytes (56), and in two non-precursor 
fibroblast cell lines: BALB/c and NIH-3T3 cells (57). Of note, STAT5B was unable to display 
similar proadipogenic properties in these non-precursor cells (57). Studies have shown that the 
growth hormone activated STAT5 proteins can induce PPARγ expression in 3T3-L1 cells and 
C3H10T1/2 cells (58), suggesting a mechanism by which STAT5 proteins are able to promote 
adipocyte differentiation. Interestingly, transgenic knockout experiments have shown that 
disruption in either STAT5A or STAT5B or both genes resulted in abnormal adipose tissue and 
mice lacking both STAT5 proteins had fat pads one-fifth the normal size (59). To date, there are 
no studies on tissue specific knockout of STAT5 genes in adipocytes and the phenotype of the 
STAT5 null mice could be attributed to developmental effects of STAT5 that are independent of 
direct effects on preadipocyte differentiation. However, recent observations have demonstrated 
that ectopic STAT5A expression can confer the adipogenic capabilities of Swiss 3T3 fibroblasts 
in athymic mice (60). In addition to demonstrating a direct role of STAT5A in preadipocyte 
differentiation in vivo, these studies also demonstrate the usefulness of athymic mice in studying 
the role of transcription factors in adipose tissue development. In summary, the importance of the 
STAT5 proteins in adipogenesis has been demonstrated in vitro and in the whole animal. 
Peroxisome Proliferator-activated Receptorγ (PPARγ): There are  many 
proadipogenic transcription factors that have been characterized, but none are as critical as 
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PPARγ, the master regulator of adipocyte differentiation and gene expression. Of note, the 
majority of identified repressors and activators of adipogenesis have been shown to modulate 
PPARγ expression and/or activity. Studies using in vitro models of adipogenesis have 
consistently shown that PPARγ mRNA is induced by several transcription factors including 
C/EBPβ, C/EBPδ, EBF1, and KLF5. Repressors of adipogenesis such as GATA2, KLF2, and 
CHOP have been shown to attenuate PPARγ expression (reviewed in (61)). PPARγ is a member 
of a super family of hormone nuclear receptors, and has been shown to be crucial and sufficient 
for adipocyte development in vitro and in vivo (62-64). In 1995, the anti-diabetic 
thiazolidinediones (TZDs) drugs were shown to be high affinity PPARγ ligands (65). This study 
was the first to indicate that PPARγ was a target for this anti-diabetic class of drugs. PPARγ 
proteins are expressed in two forms, PPARγ1 and PPARγ2 that are produced by a combination 
of alternative promoter usage and alternative splicing (66). PPARγ1 is expressed at low levels in 
multiple tissues while PPARγ2 is highly expressed in fat cells and differs from PPARγ1 by an N-
terminal extension of 30 amino acids (64). A key regulatory role of PPARγ in fat cell 
differentiation was observed by gain of function experiments that revealed that ectopic 
expression and activation of PPARγ in fibroblasts or myocytes promoted adipogenesis (62;64). 
Recent studies have shown that PPARγ2, but not PPARγ1, profoundly affects adipogenesis (67) 
and that only increases of PPARγ2 were observed in adipocytes of morbidly obese individuals 
(68). Although these studies suggest differential roles of the PPARγ isoforms, a study in PPARγ 
null cells demonstrated that both PPARγ1 and PPARγ2 can stimulate robust adipogenesis (69). 
However, PPARγ2 exhibits an enhanced ability to confer adipogenesis due to its increased 
sensitivity to ligands and enhanced ability to bind components of the DRIP/TRAP complex (69).  
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In vivo studies have shown that PPARγ deletion in mice results in placental dysfunction 
and embryonic lethality (70). To overcome this developmental limitation, fat specific knockout 
mice and mice in which placental dysfunction was averted were engineered in order to study the 
proadipogenic capabilities of PPARγ. The use of these mouse model systems has demonstrated 
that  PPARγ is critical for fat cell development (63) and mice with adipose tissue specific loss of 
PPARγ display decreased  fat pad size and insulin resistance in adipose tissue and liver (71). 
Although PPARγ is required for adipogenesis, there is evdience to suggest that this nuclear 
receptor may  not be needed to maintain the differentiated state of the cell after adipogenesis 
(72). Of note, PPARγ heterozygote mice exhibit enhanced insulin sensitivity (73), suggesting the 
amount of protein present is highly important. The importance of PPARγ in human adipose 
tissue has also been established and subjects with mutations in the PPARγ gene can develop 
severe insulin resistance and lipodystrophy (74-76).  Taken together, these studies demonstrate 
the requirement for PPARγ in adipocyte differentiation and whole body insulin sensitivity.   
 The expression and activity of PPARγ can be modulated by various pathways, and 
several studies in the last decade have focused on the post-translational regulation of this nuclear 
receptor.  In particular, the ubiquitin-proteasome system has emerged as an important regulator 
of PPARγ (77-79). Both the AF-1 and ligand-binding domains (LBDs) of PPARγ are targeted to 
the proteasome for degradation, but only the LBD is conjugated to ubiquitin (80). Of note, a fully 
functional ubiquitin system is required for PPARγ activation (80). Overall, these studies indicate 
that the ubiquitin-proteasome pathway is an integral determinant of PPARγ activity and that this 
nuclear receptor is targeted to the proteasome for degradation via ubiquitin independent and 
ubiquitin dependent mechanisms. Small ubiquitin-like modifier (SUMO), a protein structurally 
homologous to ubiquitin, is another important regulator of PPARγ. SUMOylation can occur in 
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the AF-1 domain at Lys
107
 of PPARγ2, or Lys
77
 of PPARγ1 to control stability and activity (81-
84). PPARγ can also be SUMOylated in a ligand-dependent manner in the LBD at Lys
365
 (83). 
Another regulatory covalent modification of PPARγ is phosphorylation at Ser
112 
by mitogen-
activated protein kinases (MAPK) such as p44/p42
 
(ERKs 1 and 2) and c-Jun amino-terminal 
kinase (JNK), which results in transcriptional inactivation of PPARγ (85). Although it is widely 
accepted that phosphorylation of PPARγ2 inhibits its activity, a point mutation at Ser
112
 does not 
disrupt the ability of PPARγ2 to confer adipogenesis (86). However, in vivo studies have shown 
that PPARγ2 phosphorylation at this residue modulates insulin sensitivity in the setting of diet-
induced obesity (86). Very recent studies have revealed CDK5 phosphorylates PPARγ at Ser
273
 
to attenuate PPARγ trans-activation of important adipocyte genes including adiponectin (87). 
The tigthly controlled regulation of PPARγ by ubiquitylation, SUMOylation, and 
phosphorylation indicates the importance of modulating the expression and activity of this 
master regulator of adipogenesis.  
1.3.2 Negative Effectors of Adipocyte Development 
Wnt Signaling: The Wnt family is a group of more than sixteen secreted glycoproteins 
that has pleiotropic effects on cell fate specification, proliferation, and differentiation (reviewed 
in (88)). Wnts signal in an autocrine or paracrine manner through the Frizzled receptors, or low 
density lipoprotein receptor-related protein (reviewed in (89)).  Upon binding its Frizzled 
receptor, Wnt activates the canonical pathway that inhibits glycogen synthase kinase 3 (GSK3) 
and results in an increase of cytosolic β-catenin which then translocates to the nucleus where it 
binds to the T-cell factor/lymphoid-enhancing factor (TCF/LEF) transcription factors to regulate 
the expression of Wnt target genes (reviewed (88)). Within the past decade, microarray analyses 






Figure 1 Positive and negative effectors that regulate adipogenesis. Several transcription 
factors can promote adipocyte differentiation. This sequence begins with the induction of AP-1 
transcription factors, followed by the activation of other proadipogenic transcription factors. 












As shown in Figure 1, Wnt signaling inhibits fat cell differentiation by reducing the expression 
of PPARγ and C/EBPα in 3T3-L1 and 3T3-F442A cells (90;92;93). Of note, activation of the 
Wnt pathway attenuates the expression of brown adipocyte marker genes UCP-1 and PGC-1α 
while the expression of other adipocyte genes are maintained (94). To further examine the effects 
of Wnts on adipogenesis, researchers engineered transgenic mice that express ectopic Wnt 10b 
using the aP2 promoter. These mice exhibited a 50% reduction in white adipose tissue and 
severely reduced brown adipose tissue. Interestingly, this inhibition of adipose tissue 
development did not result in lipodystrophic diabetes and these mice exhibited enhanced insulin 
sensitivity (95).  
GATA Factors: There are six members of this zinc finger domain family of transcription 
factors, designated GATA 1 – 6. These transcription factors bind to specific (A/T)GATA(A/G) 
DNA consensus sequences to regulate cell differentiation and proliferation (96). Of the six 
factors, only GATA-2 and -3 are expressed in preadipocytes that are present in WAT but not in 
BAT (97).  The expression of these transcription factors is repressed during adipocyte 
differentiation which suggests that GATAs 2 and 3 exert antiadipogenic effects on preadipocytes 
(see Figure 1). In support of this hypothesis, GATA 2-deficient embryonic stem cells exhibit an 
enhanced differentiation potential and ectopic expression of GATA-2 partially reduces fat cell 
development by directly binding to a PPARγ promoter region to repress basal activity (97). 
GATA-2 and 3 can also associate with C/EBPs α and β to disrupt their transcriptional activity 
(98), suggesting GATA can attenuate adipogenesis via multiple pathways. GATA proteins can 
be regulated post-translationally by acetylation, SUMOylation, and phosphorylation (99-101). 
Akt phosphorylation of GATA results in cytosolic sequestering and inhibition of nuclear 
translocation (101).  Recent studies have suggested that friend of GATA (FOG) and C-terminal 
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binding proteins (CTBPs) act together with GATA-2 as co-regulators of adipocyte proliferation 
and differentiation (102).  
Krüppel-like Factors (KLFs): As indicated above, KLFs 4, 5, 6, and 15 promote 
adipogenesis. However other members of the KLF family can inhibit fat cell differentiation. 
Studies have shown that KLF2 and KLF7 are negative regulators of fat cell differentiation. KLF2 
mRNA is highly expressed in preadipocytes present in adipose tissue and its expression is 
decreased during adipogenesis. Ectopic expression of KLF2 in 3T3-L1 preadipocytes 
significantly disrupts lipid accumulation by repressing PPARγ2 gene expression (103) and 
partially restoring preadipocyte factor-1 (PREF-1) expression (104). The effect of KLF2 on 
adipocyte development is also evident in mouse embryonic fibroblasts derived from KLF2
-/- 
mouse embryos that exhibit enhanced lipid accumulation (104).  Ectopic expression of KLF7, 
another negative regulator of adipogenesis in human preadipocytes significantly inhibits 
adipocyte development and expression of PPARγ and C/EBPα (105).  
Preadipocyte Factor-1 (Pref-1): Pref-1 was identified in a 3T3-L1 cDNA library for its 
enriched expression in preadipocytes (106). Delta-like protein-1 (DLK-1) is the human 
homologue of Pref-1 and was originally identified by purification from fetal circulation as fetal 
antigen-1 (107). Pref-1 is a transmembrane protein that belongs to a family of EGF-repeat 
containing proteins and shares structural homology with the Notch/Delta/Serrate proteins 
(reviewed in (108)). Pref-1 is activated by proteolytic cleavage to regulate cell fate specification 
(109). This protein is abundantly expressed in preadipocytes but levels substantially diminish 
during adipocyte development (110). Constitutive expression of Pref-1 reduces PPARγ and 
C/EBPα expression and inhibits the differentiation of 3T3-L1 preadipocytes  (106). Pref-1 
deficient mice exhibit growth retardation and accelerated adiposity (111). Transgenic mice with 
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aP2 mediated ectopic expression of Pref-1 in adipose tissue results have severe lipoatrophy, 
impaired glucose tolerance, and hypertriglyceridemia (112). 
1.3.3 Endocrine Regulation of Adipogenesis 
Thyroid Hormone: Thyroid hormones, triiodothyronine (T3) and thyroxine (T4) are 
controlled by a well studied classic negative feedback loop. T3, the biologically active form of 
the hormone, has pleiotrophic effects on various physiological processes and is a key regulator of 
metabolism and development. Thyroid hormone action is mediated through a family of nuclear 
thyroid hormone receptors that can repress transcription in a ligand-independent manner. An 
association between thyroid hormone and adipose tissue development has been established since 
1888 when a study on myxedema suggested that obesity was a prerequisite for a diagnosis of 
hypothyroidism (reviewed in (113)). Rodent hyperthyroidism induces adipocyte hyperplasia, 
whereas hypothyroidism impedes adipose tissue development (114).  
It is well known that T3 induces brown adipocyte differentiation. T3 supplemented media 
is commonly employed to stimulate differentiation of cultured brown adipocytes (115). The 
effect of thyroid hormone on lipogenesis has been observed in Sprague-Dawley rats treated with 
T3 (116), suggesting that thyroid hormone can induce the expression of lipogenic genes. Studies 
investigating the involvement of thyroid hormones in adipose tissue development are 
controversial. To date, there remains no concrete mechanism of thyroid hormone action in the 
adipogenic program. Nonetheless, it is clear that thyroid hormones are capable of regulating 
adipocyte development and modulating the expression of genes required for lipogenesis.   
Steroid Hormones: Steroid hormones regulate the distribution and development of fat in 
mammals. Hence it is not surprising that adipocytes express abundant levels of steroid hormone 
receptors. The actions of steroid receptors are mediated by genomic responses and events that are 
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independent of transcription. This section will focus on the effects of estrogen (E2), androgens, 
and glucocorticoids on adipocyte differentiation. The receptor mediated effects of estrogen occur 
via two receptors, ER-α and ER-β to regulate metabolism and adipose tissue distribution 
(117;118). Potential gene targets of E2 can be estimated by the expression and distribution of its 
receptors. Studies investigating the expression patterns of ER-α and ER-β demonstrated that they 
are expressed in rat and human preadipocytes, mature adipocytes and other cell types present in 
adipose tissue including macrophages (119-121). Various studies have shown that E2 regulates 
adipocyte differentiation, however, the results are contradictory. Estrogen has been reported to 
induce the differentiation of 3T3-L1, female rat subcutaneous, and human preadipocytes 
(122;123). However, another study showed that estrogen inhibits 3T3-L1 preadipocyte 
differentiation (124).  In vivo studies have yielded more consistent observations on the effects of 
estrogen on adipocyte development. Both male and female ER-α deficient mice have increased 
WAT accumulation, and insulin resistance (125). Studies using E2 deficient rodent models also 
supported the inhibitory effect this hormone on adiposity. Aromatase deficient mice (ArKO) 
develop increased fat pad mass, hyperinsulinemia, hyperlipidemia and liver steatosis (126). Mice 
deficient of follicle-stimulating hormone receptor exhibit increased development of visceral fat 
(127). Collectively, the majority of studies suggest that estrogen attenuates adipocyte 
development.  
Androgens also regulate fat cell metabolism and adipose tissue distribution (117;118). 
Androgens can be found in adipocytes (128), and there is substantial evidence to demonstrate 
that the androgen receptor (AR) is expressed in rat (129;130) and human (131) preadipocytes and 
adipocytes. Together, these observations indicate that fat cells are targets of androgen action. As 
observed with estrogen experiments, in vitro studies have shown opposing effects of androgens 
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on the differentiation of preadipocytes. One study concluded that androgens induced rat fat cell 
development (132), whereas other studies have reported that androgens inhibit adipocyte 
differentiation (124;133;134). It was proposed that the two potent androgens, testosterone and 
dihydrotestosterone (DHT) decrease C/EBPα and PPARγ2 expression to inhibit differentiation of 
3T3-L1 cells (135). Additionally, transgenic mice with targeted AR overexpression in 
mesenchymal stem cells have substantial reductions in both WAT and BAT depots (136). In 
summary, the majority of studies on androgens and adipocyte development suggest that these 
steroid hormones have inhibitory effects.  
Glucocorticoids (GCs) are another class of steroid hormones that regulate adipocyte 
differentiation. The glucocorticoid receptor (GR) is expressed in most cell types and GCs bind to 
GR to mediate effects on metabolism and immune response (137). It is well established that GCs 
promote adipogenesis. Dexamethasone (DEX), a synthetic GC, is a standard component of the 
hormonal induction cocktail used to induce 3T3-L1 preadipocyte differentiation (138). Today, 
there is ubiquitous laboratory use of DEX to   promote adipogenesis in a variety of cell lines 
including 10 T1/2 (139) and Ob1771 (140) cells. Mechanistic studies indicate that DEX induces 
C/EBPδ (25), which plays a role in the induction of the master adipogenic regulator PPARγ 
(141).  
Peptide Hormones: A large variety of peptide hormones can modulate adipogenesis, 
including growth hormone (GH) and insulin. Both preadipocytes and adipocytes are responsive 
to GH. GH primarily signals via the JAK/STAT signaling pathway. As indicated earlier in this 
review, STAT5 proteins promote adipogenesis in vitro and in vivo (43;56;59;142). Since GH is a 
potent activator of STAT5, it is not surprising that most studies show that GH promotes 
adipocyte development. Recent studies have indicated that the GH/STAT5 pathway enhances 
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both the expression and the activity of C/EBPs β and δ and PPARγ (58), thus proposing multiple 
pathways through which GH promotes adipogenesis. Earlier studies demonstrated that GH exerts 
a dual effect on 3T3-F442A preadipocytes where there is an initial direct effect on preadipocytes 
to initiate the adipogenic program that is followed by an indirect effect of GH to induce insulin-
like growth factor-1 (IGF-1) to stimulate growth of the committed cells (143).  While it has been 
clearly established that GH promotes adipocyte development in clonal cell lines, several studies 
show an opposing effect of GH action on differentiation of primary cultured preadipocytes. In 
primary rat and human preadipocytes, GH inhibits differentiation (144;145).  
Many investigators who use adipocytes assume that insulin is a positive regulator of fat 
cell development. However, the use of insulin in the standard hormonal cocktail is at 
supraphysiological hormone levels that are capable of  activating IGF-1 receptor signaling (146). 
Nonetheless, there is evidence that insulin signaling can modulate the expression of genes 
required for adipocyte development and physiology in the whole animal. Mice that lack the 
insulin receptor in adipose tissue exhibit reduced fat mass and decreased levels of SREBP-1 and 
C/EBPα in white adipocytes. Additionally, these mice exhibit abnormally high leptin serum 
levels (147). In summary, these studies suggest that insulin can promote adipogenesis, however 
more studies are necessary to clarify the mechanism(s) of action. 
1.4 Adipokines 
The term adipokine refers to any growth factor, hormone, or cytokine that is synthesized 
and secreted from adipose tissue. Adipokines regulate key physiological processes such as 
satiety, energy homeostasis, insulin sensitivity, blood pressure, and inflammation. In 1994, 
Zhang and colleagues revealed that the satiety hormone leptin is produced in adipose tissue 
(148). This was the first study to show that adipose tissue is a bonafide endocrine organ.  
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Table 1 Endocrine Regulation of Adipogenesis 

















































CNTF No effect (149) 
CT-1 No effect (150) 
IL-11 Inhibitory (151-153) 
LIF Controversial 
No effect (154;155) 
Pro-adipogenic (156) 
Anti-adipogenic (157) 
NP Inhibitory (155) 






Following this ground breaking discovery, Scherer and colleagues identified a second hormone 
exclusively secreted from adipocytes in 1995. This hormone was characterized as adipocyte 
complement-related protein of 30 kD (Acrp30) (159) and is also referred to as AdipoQ (160), 
adipose most abundant gene transcript-1 (apM1) (161) ,  gelatin-binding protein of 28 kD 
(GBP28) (162). Now, this adipocyte specific hormone is commonly known as adiponectin. 
Adiponectin is a pleiotropic hormone that regulates several processes. However the most clearly 
understood are glucose and lipid metabolism (163;164). Also, adiponectin has also been shown 
to be cardio-protective in mice and humans (165;166) and more recent studies indicate 
adiponectin can act on the brain to regulate satiety (167).  
  In 2000, another adipocyte specific hormone was identified as a member of the “found in 
inflammatory zone” (FIZZ) family, and was labeled FIZZ3 (168). Immunoneutralization studies 
suggested that this hormone, now widely referred to as resistin, might be involved in the 
pathogenesis of insulin resistance (169).  In these studies, investigators observed improved 
insulin sensitivity when anti-resistin IgG was administered to rodents with obesity/Type II 
Diabetes Mellitus (T2DM). It is important to note that the distribution pattern of resistin in 
humans is different from mice. Several groups have shown that resistin is expressed at low levels 
in human adipocytes (170-172), but the majority of resistin expressed in humans is found in 
monocytes and macrophages that reside in adipose tissue at higher levels compared to amounts 
observed in adipocytes (172;173). A highly innovative experiment from the Lazar laboratory 
sought to determine if the resistin derived from human macrophages was sufficient to confer 
insulin resistance. In this study, researchers engineered a mouse model that was deficient of 
adipocyte-derived resistin and produced human resistin from a macrophage-specific promoter. 
These mice are referred to as the humanized resistin mice and they exhibit a phenotype of insulin 
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resistance and white adipose tissue inflammation (174). These studies indicate that resistin has 
similar functions in mice and man despite the differences in expression. 
1.5 Glycoprotein 130 (gp130) Cytokines 
The family of gp130 cytokines regulate a variety of complex biological processes 
including hematopoiesis, immune response, inflammation, proliferation, differentiation, 
mammalian reproduction, cardiovascular action, and neuronal survival (reviewed in (175)). 
These cytokines share glycoprotein 130 as a common signal transducer in their receptor complex 
and typically activate STAT3, a latent transcription factor. The gp130 family is also referred to 
as the Interleukin (IL)-6 family of cytokines and is a group of functionally and structurally 
related proteins that includes Interleukin-6 (IL-6), Interleukin-11 (IL-11), Interleukin-27 (IL-27), 
leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), 
cardiotrophin-1 (CT-1), novel neurotrophin-1/B cell stimulating factor-3 or cardiotrophin-like 
cytokine (CLC), and neuropoietin (NP) (reviewed in (176)). The gp130 cytokines have become a 
focus in T2DM and obesity research in the past decade. Several studies have shown that gp 130 
cytokines can regulate adipocyte differentiation and function in vivo and in vitro (177-182). To 
date, no gp130 cytokines have been shown to promote adipogenesis, but as shown in Table 1 
several cytokines in this family have been shown to inhibit adipocyte development 
(149;150;152-155;158;183;184). However, the mechanisms involved in gp 130 cytokine actions 
in adipose tissue have not been fully elucidated.  
This thesis highlights a potential role of CT-1 in the association between T2DM, obesity 
and heart disease. It is well established that there is a link between cardiovascular disease and 
T2DM, and many studies show that CT-1 serum levels are modulated in various heart diseases 
including hypertension, myocardial infarction, ischemia, and cardiomyopathy (reviewed in 
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(185)). Further, cardiovascular disease is the leading cause of mortality in patients with T2DM. 
CT-1 is a 21.5kD molecule that was identified in 1995 in a cDNA screen of murine embryoid 
bodies for its ability to promote cardiomyocyte survival, proliferation, and hypertrophy 
(186;187). High levels of CT-1 mRNA is has been detected in a variety of tissues including the 
heart, skeletal muscle and liver (188). Interestingly, recent studies revealed that CT-1 is 
expressed in adipose tissue (189).  
1.5.1 Molecular Regulation of Cardiotrophin-1 Expression 
To date, the majority of studies investigating possible regulatory factors of CT-1 
expression have largely been conducted in cultured cardiomyocytes and rodent models of various 
heart diseases. Several independent studies in the last decade have shown that CT-1 mRNA and 
protein expression can be modulated by endocrine action or by intracellular factors.  Isolation 
and characterization of the CT-1 gene and promoter revealed several putative binding sites for 
various transcription factors including hypoxia-inducible factor-1 (HIF-1), C/EBPβ, and GATA1 
(190;191).  However, more studies are necessary to further elucidate the mechanisms involved in 
modulating CT-1 expression.  
Studies by Hishinuma in 1999 suggested that hypoxic stress was capable of inducing CT-
1 mRNA expression in primary cultured cardiac myocytes (192). It was later demonstrated that 
CT-1 expression was increased upon induction and stabilization of the α-subunit of HIF-1, in 
embryonic cardiomyocytes exposed to hypoxia or reactive oxygen species (ROS)  (193). These 
studies demonstrate that CT-1 can be cardio-protective against ischemia-reperfusion injury. CT-1 
expression can also be regulated by endocrine factors. Hormones such as aldosterone, 
norepinephrine and fibroblast growth factor-2 (FGF-2) are capable of modulating CT-1 
expression. It is well established that substantially high aldosterone serum levels are observed in 
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patients with hypertension (194;195). Thus, is not surprising that aldosterone is a potent inducer 
of CT-1 expression in HL-1 mature cardiomyocytes and rodent models of aldosterone over-load 
(196). These studies demonstrate a role for CT-1 in vascular wall re-modeling in hypertension. 
These studies underscore the cardio-protective functions of CT-1. It is therefore important 
identify other potential physiological sources of CT-1 and, to understand the mechanisms 
through which CT-1 levels are modulated in various pathologies including T2DM. 
1.6 In vitro and In vivo Model Systems 
3T3-L1 Cultured Adipocytes: A variety of cellular models systems are widely used to 
study the molecular pathways of adipogenesis and adipocyte function in vitro. These models can 
be largely placed in two classes. The first group of model systems is pluripotent fibroblasts that 
have the ability to differentiate into several cell types including myocytes, chondrocytes, and 
adipocytes. This class includes the 10T½, Balb/c 3T3, 1246, RCJ3.1 and CHEF/18 fibroblast cell 
lines. The second group of model systems is comprised of fibroblast-like unipotent preadipocytes 
that are committed to differentiating into adipocytes. This group includes 3T3-L1, 3T3-F422A, 
1246, Ob1771, TA1 and 30A5 preadipocytes. This latter class represents the most frequently 
used cells to study adipogenesis and fat cell physiology. Howard Green and colleagues 
established the 3T3-L1 line in 1976. This cell line has been extensively characterized and 
utilized in adipocyte biology. 3T3-L1 preadipocytes were derived from disaggregated 17-19 day 
old Swiss 3T3 mouse embryos (197;198) and require glucocorticoid supplemented 
differentiation cocktail to induce adipogenesis (138;199;200). The 3T3-L1 cell line is preferred 
over other in vitro models because they develop into a homogenous population of mature 
adipocytes that are morphologically (201) and biochemically (202) similar to adipocytes in situ.  
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C57BL/6 Mice: The C57BL/6 mouse is an appropriate model system for human 
metabolic syndrome. Several lines of studies have demonstrated that the majority of instances of 
human obesity and subsequent development of T2DM occurs as a result of high-fat or western 
diets (203;204). The C57BL/6 mouse is an inbred model system that can develop severe obesity, 
hyperglycemia, hyperinsulinemia, and cardiovascular disease when fed a 55% Kcal high fat diet 
for approximately ten weeks (205-207). Further to this, it has been reported that C57BL/6 mice 
fed a fat enriched diet exhibit selective visceral distribution of white adipose tissue (206;208). Of 
note, there is a strong correlation between human visceral obesity and life threatening 
pathologies including T2DM and cardiovascular disease (reviewed in (209)). Hence, it is widely 
accepted that the progression of metabolic syndrome that occurs in response high fat feeding in 





MATERIALS AND METHODS 
2.1 Materials 
Dulbecco’s Modified Eagle’s Media (DMEM) was purchased from Sigma. Bovine and fetal 
bovine (FBS) sera were purchased from Atlanta Biological. Murine recombinant CT-1 was 
purchased from R&D Systems. Human polyclonal and murine monoclonal CT-1 antibodies were 
purchased from R&D Systems. STAT 5A and adipsin polyclonal antibody were purchased from 
Santa Cruz Biotechnology. Nitrocellulose and Zeta Probe-GT membranes were purchased from 
Bio-Rad. The BCA kit and the enhanced chemiluminescence kit were purchased form Pierce. 
Horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Jackson 
ImmunoResearch Laboratories. Glycoprotein deglycosylation kit was purchased from 
Calbiochem. 
2.2 Cell Culture 
Murine 3T3-L1 preadipocytes were plated and grown to 2 days post-confluence in DMEM 
containing 10% bovine serum. Medium was changed every 48 h. Cells were induced to 
differentiate by changing the medium to DMEM containing 10% fetal bovine serum (FBS), 0.5 
mM 3-isobutylmethylxanthine, 1 μM dexamethasone, and 1.7 μM insulin (MDI). After 48 h, this 
medium was replaced with DMEM supplemented with 10% FBS and cells were maintained in 
this medium until utilized for experimentation. In some experiments, cells were induced to 






2.3 Preparation of Whole Cell Extracts and Media 
Cell monolayers of 3T3-L1 adipocytes were harvested in a non-denaturing buffer containing 150 
mM NaCl, 10 mM Tris, pH 7.4, 1 mM EGTA, 1 mM EDTA, 1% Triton-X 100, 0.5% Igepal CA- 
630, 1 μM phenylmethylsulfonyl fluoride (PMSF), 1μM pepstatin, 50 trypsin inhibitory 
milliunits of aprotinin, 10 μM leupeptin, and 2 mM sodium vanadate and frozen. Next, the 
samples were thawed and centrifuged at 13,000 rpm at 4
o
C for 10 minutes. Supernatants 
containing whole cell extracts were analyzed for protein content using a BCA kit according to 
the manufacturer’s instructions. Media of 3T3-L1 adipocytes was collected under non-denaturing 
conditions using 1 μM phenylmethylsulfonyl fluoride (PMSF) and frozen. Next, the samples 
were analyzed for protein content using a BCA kit according to the manufacturer’s instructions. 
2.4 Rodent Adipose Tissue Isolation  
12 week old C57BL/6 mice were euthanized with CO2, and tissues were immediately removed 
and frozen in liquid nitrogen. Frozen tissues were homogenized in a buffer containing 150 mM 
NaCl, 10 mM Tris, pH 7.4, 1mM EGTA, 1mM EDTA, 1% Triton-X 100, 0.5% Igepal CA-630, 1 
μM PMSF, 1 μM pepstatin, and trypsin inhibitory milliunits of aprotinin, 10 μM leupeptin, and 2 
mM sodium vanadate. Homogenates were centrifuged for 10 minutes at 1000 x g to remove any 
debris and insoluble material and then analyzed for protein content. All animal studies were 
carried out with protocols which were reviewed and approved by institutional animal care and 
use committees. 
2.5 Gel Electrophoresis and Western Blot Analysis 
Proteins were separated in 7.5% polyacrylamide (acrylamide from National Diagnostics) gels 
containing sodium dodecyl sulfate (SDS) according to Laemmli (210) and transferred to 
nitrocellulose membrane in 25 mM Tris, 192 mM glycine, and 20% methanol. Following 
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transfer, the membrane was blocked overnight in 4% milk at 4
o
C and subsequently exposed to 
the appropriate antibodies. Results were visualized with horseradish peroxidase (HRP)-
conjugated secondary antibodies and enhanced chemiluminescence. 
2.6 RNA Analysis 
Total RNA was isolated from cell monolayers with Trizol according to the manufacturer’s 
instructions with minor modifications. For Northern blot analysis, 20 μg of total RNA was 
denatured in formamide and electrophoresed through a formaldehyde/agarose gel. The RNA was 
transferred to Zeta Probe-GT, cross-linked, hybridized, and washed as previously described 
(211). Probes were labeled by random priming using Klenow fragment and [α 
32
P] dATP. 
2.7 Immunoprecipitation (IP) of Cardiotrophin-1  
Cells were harvested under non-denaturing conditions, and the protein content of the whole-cell 
extracts was analyzed as described above. After a single freeze-thaw cycle, the protein extracts 
were preincubated with protein A agarose, and the resulting supernatant was then incubated with 
2 μg of human polyclonal CT-1 antibodies for 1 hour at 4 °C. Protein-A agarose (Repligen 
Corporation, Waltham, MA) was added to the mixture, and the sample was rotated for an 
additional hour. Bound CT-1 was isolated by pelleting this mixture. The pellets were rinsed three 
times with phosphate-buffered saline, and bound proteins were eluted from the agarose by 
incubation at 100 °C for 10 minutes after the addition of Laemmli sample buffer. These samples 
were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and 




CARDIOTROPHIN-1 EXPRESSION IS DIFFERENTIALLY REGULATED IN MURINE 
AND HUMAN TYPE II DIABETES AND OBESITY 
 
The white adipose tissue, heart, spleen, liver, skeletal muscle, kidney, and brain of an 8-
week-old male Sprague Dawley rat was examined for CT-1 mRNA expression. Additionally, 
total RNA of 3T3-L1 mature adipocytes was examined for CT-1 mRNA. We were able to detect 
CT-1 mRNA in 3T3-L1 cultured adipocytes and rodent white adipose tissue.  
 
 
Figure 3.1 CT-1 mRNA is highly expressed in adipose tissue and 3T3-L1 adipocytes. Total 
RNA was isolated from tissue obtained from an 8-week-old Sprague Dawley male rat and from 
mature 3T3-L1 adipocytes using Trizol reagent. 20 μg of total RNA was electrophoresed, 
transferred to nylon and subjected to Northern blot analysis. 
 
 As shown in Figure 3.1, CT-1 mRNA is highly expressed in the rat adipose tissue sample that 
was a mixture of both epididymal and retroperitoneal fat. CT-1 mRNA was also expressed at 
high levels in fully differentiated 3T3-L1 adipocytes. As predicted, CT-1 mRNA was also 
detectable in the heart. We observed lower mRNA levels in liver, skeletal muscle, and kidney. 
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aP2 is a lipid-binding protein that is abundantly expressed in adipocytes, and was used as a 
positive control. β-actin was used as a loading control.   
CT-1 is readily detected in both rodent and human serum (212-214). We hypothesized 
that adipocytes were capable of secreting CT-1. 3T3-L1 preadipocytes were induced to 
differentiate using media containing 3-isobutyl-1-methylxanthine, dexamethasone, and high 
doses of insulin (MDI). This process prompts 3T3-L1 cells to undergo postconfluent mitotic 
clonal expansion, exit the cell cycle, and begin to express adipocyte-specific genes (138). Media 
was then obtained at 10 and 20 days post MDI in the presence of 1μL PMSF and examined for 
CT-1 protein. As shown in Figure 3.2, we observed that the CT-1 dimer was detectable in the 
media of 3T3-L1 adipocytes. Adiponectin, an adipocyte-specific hormone was used as a positive 
control for this experiment.  
 
Figure 3.2 CT-1 is secreted from 3T3-L1 adipocytes. 3T3-L1 adipocytes were induced to 
differentiate and media was obtained at 10 and 20 days post MDI in the presence of 1μL PMSF. 
The samples were then separated by SDS-PAGE, transferred to nitrocellulose and subjected to 




Our results in rodent adipose tissue, cultured murine adipocytes, and murine adipocyte media 
indicate that CT-1 is expressed in, and secreted from adipocytes.  
The association between T2DM and cardiovascular disease has been well acknowledged. 
Since CT-1 is expressed in and secreted from adipocytes, we hypothesized that CT-1 expression 
is modulated in T2DM/obesity. We examined the epididymal and retroperitoneal adipose tissue 
of seven 12-week-old C57BL/6 mice that were fed a 60% high fat diet (HFD) for six weeks and 
seven littermates that were fed a 10% low fat diet (LFD) diet for the same period. Total RNA 
was isolated from the tissues and subjected to Northern blot analysis. As shown in Figure 3.3, 
CT-1 mRNA is decreased in the mice that developed diet induced obesity (DIO) as a result of 
being fed a diet high in fat. It is well established that adipsin expression is decreased in murine 
T2DM/obesity and we see that levels of adipsin mRNA is also decreased in mice that were 
placed on a HFD.  
 
Figure 3.3 CT-1 mRNA is decreased in WAT in DIO. Seven mice were placed on a 60% HFD 
for 6 weeks and seven were fed a 10% LFD for the same period.  Total RNA was isolated from 
epididymal fat pads of 14 male 12 week old C57BL/6 mice. Total RNA was electrophoresed, 































MCP-1 and TNFα are used as positive controls for this experiment because it is well known that 
the expression of these proteins is upregulated in adipose tissue in T2DM/obesity due to 
macrophage infiltration. Additionally, tissues of seven 12-week-old C57BL/6 mice that were fed 
a 60% HFD for six weeks and seven littermates that were fed a 10% LFD for the same period 
were homogenized using a non-denaturing buffer and subjected to Western blot analysis. As 
shown in Figure 3.4, we observed a substantial decrease in CT-1 protein expression in C57BL/6 
mice that were subjected to a HFD. Data for three animals of each condition is shown. Adipsin is 
used as a control for this experiment and STAT5A is used as a loading control, because it is not 
regulated in T2DM/obesity.  Next, we sought to determine whether CT-1 protein expression was 
modulated in other tissues of mice with T2DM/obesity. For this experiment, we analyzed the 
heart, skeletal muscle and liver of the same mice that were used in the previous experiment. 
 
 
Figure 3.4 CT-1 protein expression is substantially decreased in WAT of DIO. Epididymal 
and retroperitoneal fat pads were obtained from male C57BL/6 mice after 12 week feeding of a 
10% LFD or 60% HFD. Tissues were homogenized using a non-denaturing buffer and separated 
by SDS-PAGE, transferred to nitrocellulose and subjected to Western blot analysis. Data for 
three mice of each condition is shown.  
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Figure 3.5 CT-1 protein expression is substantially decreased in tissues of DIO. Heart, 
skeletal muscle, and liver samples were obtained from male C57BL/6 mice after 12 week 
feeding of 10% LFD or 60% HFD. Tissues were homogenized using a non-denaturing buffer and 
separated by SDS-PAGE, transferred to nitrocellulose and subjected to Western blot analysis. 
Data for three mice of each condition is shown.  
 
Surprisingly, we found that CT-1 protein expression was substantially decreased in these 
tissues as well (Figure 3.5). Taken together, our data present novel findings that CT-1 mRNA 
and protein expression is decreased in murine T2DM/obesity. 
To determine whether CT-1 protein is expressed in human adipose tissue, we analyzed 
the adipose tissue derived from human lipoaspirate. Human adipose tissue was homogenized 
using a non-denaturing buffer, the adipocyte and stromal-vascular fractions were then separated 
by SDS-PAGE and subjected to Western blot analysis. Interestingly, CT-1 protein was detectable 
in human adipose tissue in both the monomeric and dimeric form (Figure 3.6). Additionally, it 
was observed that CT-1 was present in the stromal-vascular fraction of human adipose tissue. 
Adiponectin is abundantly expressed in mature adipocytes and is used as a positive control for 







Figure 3.6 CT-1 is expressed in human adipose tissue. Human adipose tissue was 
homogenized using a non-denaturing buffer. The adipocyte and stromal vascular fractions were 
separated by SDS-PAGE and subjected to Western blot analysis.    
 
To determine whether CT-1 protein expression is modulated in human obesity, we 
examined the white adipose tissue of male and female obese patients. The lipoapirate of six lean, 
and six obese male and female patients was homogenized using a non-denaturing buffer, the 
adipocyte and stromal-vascular fractions were then separated by SDS-PAGE and subjected to 
Western blot analysis. Of note, no regulation of CT-1 protein expression was observed among 
the lean and obese male and the lean and obese female patients (Figure 3.7). The lipoaspirate of 
three lean and three obese non-diabetic patients, and three lean and three obese diabetic patients 
was examined to determine if CT-1 protein expression was modulated in human non-insulin 
dependent diabetes mellitus (NIDDM). Interestingly, no noticeable modulation in CT-1 







Figure 3.7 CT-1 expression is not regulated in human obesity. White adipose tissue from 6 
lean and 6 obese female patients and 6 lean and 6 obese male patients was homogenized using a 
non-denaturing buffer. Samples were then separated by SDS-PAGE, transferred to nitrocellulose 





Figure 3.8 CT-1 is expression is not regulated in human T2DM. White adipose tissue from 3 
lean and 3 obese non-diabetic patients and 3 lean and 3 obese diabetic patients was homogenized 
using a non-denaturing buffer. Samples were then separated by SDS-PAGE, transferred to 
nitrocellulose and subjected to Western blot analysis.  
 
In most of our experiments, we observed that CT-1 consistently migrated to a higher 
molecular weight than expected. In order to confirm that the band observed corresponded with 
CT-1, CT-1 from 3T3-L1 whole cell extract and media, and murine epididymal fat was 
immunoprecipitated using CT-1 human polyclonal antibody, and Western blot of CT-1 was 
observed using mouse monoclonal CT-1 antibody. This experiment demonstrated the specificity 






Figure 3.9 Confirmation of CT-1 detection. Whole cell extracts and media were isolated from 
fully differentiated 3T3-L1 adipocytes.  Epididymal fat pads were obtained from male C57BL/6 
mice after 12 week feeding of a 10% LFD.  Each sample was subjected to immunoprecipitation 
(IP) with a human polyclonal antibody directed against CT-1 and Western blotting analysis was 
conducted using mouse monoclonal CT-1 antibody. 300 μg of protein was used for IP, and 90 μg 
of protein was used for Western blotting. One IP contained recombinant CT-1 protein (Ctrl) and 
one contained buffer, but not extract (mock). 
 
Previous studies have reported that CT-1 contained putative sites for glycosylation (186). 
To determine whether the glycosylation is the reason for the observed migration pattern of CT-1, 
murine epididymal fat was incubated with N-Glycosidase F, Endo-α-N-acetylgalactosaminidase 
and α2-3,6,8,9-Neuraminidase to remove possible N-linked glycans.  Additionally, murine 
epididymal fat was incubated with β1,4-Galactosidase and β-N-Acetylglucosaminidase to disrupt 
possible O-linked glycans. Another sample was incubated with all endoglycosidases in order to 
remove both N-linked and O-linked glycans. As shown in Figure 3.10, glycosidase treatment did 
not alter the mobility of CT-1. The results of this experiment were repeated three times. A 
parallel experiment using bovine fetuin that was provided with the glycoprotein deglycosylation 
kit was used as a positive control (Figure 3.11). The control experiment was conducted using the 





Figure 3.10 Deglycosylation analysis of CT-1. Epididymal fat pads were prepared from male 
C57BL/6 mice after 12 week feeding of a 10% LFD. Samples were incubated with N or O 
endoglycosidases as directed by the manufacturer’s instructions and then separated SDS-PAGE, 
transferred to nitrocellulose and subjected to Western blot analysis. C1 and C2, no 
endoglycosidases; N, treatment with a mix of N-glycosidases(N-Glycosidase F, Endo-α-N-
acetylgalactosaminidase and α2-3,6,8,9-Neuraminidase); O, treatment with a mix of O-
glycosidases (β1,4-Galactosidase and β-N-Acetylglucosaminidase); N + O, treatment with both 




Figure 3.11 Deglycosylation analysis of purified bovine fetuin. Purified bovine fetuin was 
incubated with N or O endoglycosidases as directed by the manufacturer’s instructions, separated 
SDS-PAGE, and subjected to coomassie blue staining.   
 
 
 For the majority of experiments in this project, we made an interesting 
observation about the CT-1 dimer interaction. The CT-1 dimer was detectable even after 
undergoing SDS-PAGE electrophoresis, a process that typically denatures and separates proteins 
according to size and no other physical property. These observations lead to the hypothesis that 
the CT-1 monomers can form strong dimer interactions. To examine the stability of the CT-1 
dimer, media was collected from fully differentiated 3T3-L1 adipocytes in the presence of 1μL 
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PMSF. The samples were then prepared with 8% β-mercaptoethanol (β-ME), this is twice the 
concentration that is normally used, and subjected to boil at100
o
C for 15 minutes, a time period 
that is three times a greater than the standard time. Following this process, the samples were then 
separated by SDS-PAGE electrophoresis and subjected to western blot analysis. Surprisingly, as 
shown in Figure 3.12, the CT-1 dimer was detectable after being subjected to these rigorous 
conditions. These results are representative of three independent experiments. Adiponectin, an 





Figure 3.12 Analysis of CT-1 dimer. Media was obtained from fully differentiated 3T3-L1 
adipocytes. The samples were then prepared with 4% β-ME and heated to100
o
C for 5 minutes, or 
with 8% β-ME and heated to100
o
C for 15 minutes. The samples were then separated by SDS-











Obesity has emerged as a serious international epidemic and the association between 
obesity and T2DM is well established and accepted.  Additionally, the risk of developing heart 
disease as a result of T2DM/obesity has become a focus in recent decades. T2DM can adversely 
affect several metabolic processes that lead to various interconnected endothelial and vascular 
dysfunctions and result in several cardiovascular pathologies including ischemia and myocardial 
infarction. Further, cardiovascular disease is the main cause of mortality in patients with 
diabetes. However the underlying mechanisms that connect these diseases are not well 
understood (215). Thus, the purpose of this work is to present a potential link between these 
pathologies.  
Our data has shown that CT-1 is expressed in both murine and human adipose tissue. We 
were also able to show that the CT-1 dimer is detectable in the media of cultured 3T3-L1 mature 
adipocytes. To our knowledge, this is the first study to show that CT-1 is secreted from 
adipocytes. These experiments clearly demonstrate that CT-1 is produced in adipose tissue and 
our novel findings show that 3T3-L1 adipocytes can secrete the dimeric form of CT-1. It is well 
established that CT-1 is critical for cardiomyocyte survival (186), and  there is a potential link 
between T2DM/obesity and cardiovascular disease. We therefore hypothesized that CT-1 
expression would be modulated T2DM/obesity. Our results showed that CT-1 protein expression 
was substantially decreased in white adipose tissue, heart, skeletal muscle and liver in murine 
T2DM/obesity. Interestingly, we did not observe regulation of CT-1 expression in human white 
adipose tissue. This surprising finding demonstrates that the mechanism(s) governing CT-1 
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regulation may be different in mice and in humans. More studies will be necessary to elucidate 
the physiological conditions that can regulate CT-1 expression in human adipose tissue. 
In the majority of our experiments in this study, the CT-1 protein dimer migrated to 
approximately 52 kD rather than the predicted 42 kD molecular weight. To address this, we 
performed immunoprecipitation experiments to confirm that the detected protein is CT-1. Upon 
this confirmation, we then sought to determine whether CT-1 was N-linked or O-linked 
glycosylated since previous studies reported putative glycosylation sites on the CT-1 sequence 
(186). Interestingly, CT-1 mobility was not altered after samples were incubated with the 
appropriate glycosidases. Therefore, it is necessary to conduct further studies to fully understand 
the highly stable interaction between CT-1 and another approximately 10 kD molecule. 
Furthermore, it will prove valuable to characterize the substantially strong dimer interaction that 
is established between CT-1 monomers that is able to resist rigorous denaturing and dissociation 
protocols required to perform Western blot analysis.     
The novel findings presented in this study demonstrate that adipose tissue is a potential 
physiological source of circulating CT-1, and that CT-1 expression is downregulated in murine 
T2DM/obesity. It is therefore pertinent to suggest that the regulation of CT-1 in T2DM/obesity 
could be a possible link between T2DM/obesity and cardiovascular disease. Further, elucidating 
the underlying mechanism that regulates the protein expression may present therapeutic targets 
for T2DM related cardiovascular disease. While we did not observe CT-1 regulation in human 
white adipose tissue in T2DM/obesity, it is important to note that we did not examine CT-1 
expression in the heart, liver and skeletal muscle of patients with T2DM. Investigating these 
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